Breaking News

FDA Approves Recipharm Site for Manufacture of VOWST

The FDA decision provides Recipharm with a platform on which to build out its manufacturing capabilities for new modalities in the biologics space.

Recipharm, a global contract development and manufacturing organization (CDMO), announced that its subsidiary, GenIbet Biopharmaceuticals, has received U.S. FDA approval as a manufacturing site of VOWST, a breakthrough orally administered fecal microbiota product for the prevention of clostridioides difficile recurrent infection (CDI) in adults following antibacterial treatment for recurrent CDI. Recipharm will manufacture VOWST at its GenIbet site in Oeiras, Portugal on behalf of Seres Thera...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters